Engineering Antibodies for Dual Specificity and Enhanced Potency

다국어 초록 (Multilingual Abstract)

Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review.

참고문헌 (Reference)

1 Holliger, P, "“Diabodies”: small bivalent and bispecific antibody fragments" 90 : 6444-6448, 1993

2 Ridgway, J. B. B, "‘Knobs-intoholes’engineering of antibody CH3 domains for heavy chain heterodimerization" 9 : 617-621, 1996

3 Bostrom, J, "Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site" 323 : 1610-1614, 2009

4 Bargou, R, "Tumor regression in cancer patients by very low doses of a T cell–engaging antibody" 321 : 974-977, 2008

5 Weis, S. M, "Tumor angiogenesis:molecular pathways and therapeutic targets" 17 : 1359-1370, 2011

6 Hartmann, F, "Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody" 89 : 2042-2047, 1997

7 Dimitrov, D. S, "Therapeutic proteins: Methods in Molecular Biology" Humana Press 1-26, 2012

8 Jäger, M, "The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2" 69 : 4270-4276, 2009

9 Correia, I, "The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen" 5 : 364-372, 2013

10 Zeidler, R, "The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells" 83 : 261-266, 2000

11 정상택, "Tailoring Immunoglobulin Fc for Highly Potent and Serum-stable Therapeutic Antibodies" 한국생물공학회 18 (18): 625-636, 2013

12 Kim, C. H, "Synthesis of bispecific antibodies using genetically encoded unnatural amino acids" 134 : 9918-9921, 2012

13 Scheuer, W, "Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models" 69 : 9330-9336, 2009

14 Atwell, S, "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library" 270 : 26-35, 1997

15 Wu, C, "Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin" 25 : 1290-1297, 2007

16 Tarditi, L, "Selective highperformance liquid chromatographic purification of bispecific monoclonal antibodies" 599 : 13-20, 1992

17 Sebastian, M, "Review of catumaxomab in the treatment of malignant ascites" 2 : 283-286, 2010

18 Zhu, Z, "Remodeling domain interfaces to enhance heterodimer formation" 6 : 781-788, 1997

19 Nisonoff, A, "Recombination of a mixture of univalent antibody fragments of different specificity" 93 : 460-462, 1961

20 Lindhofer, H, "Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies" 155 : 219-225, 1995

21 Wu, C, "Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules" 1 : 339-347, 2009

22 Suresh, M. R, "Methods in Enzymology" Academic Press 210-228, 1986

23 Wranik, B. J, "LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies" 287 : 43331-43339, 2012

24 Schaefer, W, "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies" 108 : 11187-11192, 2011

25 Milstein, C, "Hybrid hybridomas and their use in immunohistochemistry" 305 : 537-540, 1983

26 Unverdorben, F, "Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A" 25 : 81-88, 2012

27 Roopenian, D. C, "FcRn: The neonatal Fc receptor comes of age" 7 : 715-725, 2007

28 Arndt, K. M, "Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment" 37 : 12918-12926, 1998

29 Gunasekaran, K, "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Application to bispecific molecules and monovalent IgG" 285 : 19637-19646, 2010

30 정상택, "Engineering an Aglycosylated Fc Variant for Enhanced FcγRI Engagement and pH-dependent Human FcRn Binding" 한국생물공학회 19 (19): 780-789, 2014

31 Johnson, S, "Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion" 399 : 436-449, 2010

32 Jung, S. T, "Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcãRIIa affinity and selectivity" 8 : 368-375, 2013

33 Spiess, C, "Development of a human IgG4bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines" 288 : 26583-26593, 2013

34 Seimetz, D, "Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy" 36 : 458-467, 2010

35 Kolb, H. C, "Click chemistry:diverse chemical function from a few good reactions" 40 : 2004-2021, 2001

36 Doppalapudi, V. R, "Chemical generation of bispecific antibodies" 107 : 22611-22616, 2010

37 Jung, S. T, "Bypassing glycosylation: engineering aglycosylated full length IgG antibodies for human therapy" 22 : 858-867, 2011

38 Nagorsen, D, "Blinatumomab:A historical perspective" 136 : 334-342, 2012

39 Li, B, "Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization" 73 : 6471-6483, 2013

40 Spiess, C, "Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies" 31 : 753-758, 2013

41 Segal, D. M, "Bispecific antibodies in cancer therapy" 11 : 558-562, 1999

42 Chames, P, "Bispecific antibodies for cancer therapy: the light at the end of the tunnel?" 1 : 539-547, 2009

43 Baeuerle, P. A, "BiTE: Teaching antibodies to engage T-cells for cancer therapy" 11 : 22-30, 2009

44 Scott, A. M, "Antibody therapy of cancer" 12 : 278-287, 2012

45 Schiffer, M, "Analysis of immunoglobulin domain interactions: Evidence for a dominant role of salt bridges" 203 : 799-802, 1988

46 Merchant, A. M, "An efficient route to human bispecific IgG" 16 : 677-681, 1998

47 Sazinsky, S. L, "Aglycosylated immunoglobulin G1variants productively engage activating Fc receptors" 105 : 20167-20172, 2008

48 Ju, M. S, "Aglycosylated full-length IgG antibodies: Steps toward next-generation immunotherapeutics" 30 : 128-139, 2014

49 Jung, S. T, "Aglycosylated IgG variants expressed in bacteria that selectively bind FcãRI potentiate tumor cell killing by monocyte-dendritic cells" 107 : 604-609, 2010

50 May, C, "Advances in bispecific biotherapeutics for the treatment of cancer" 84 : 1105-1112, 2012

51 Mack, M, "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity" 92 : 7021-7025, 1995

52 Fury, M, "A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors" 57 : 155-163, 2008

53 Pullarkat, V, "A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu" 48 : 9-21, 1999

54 Arndt, M. A, "A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors" 94 : 2562-2568, 1999